. . . and they deserve a standing ovation! 👏👏👏
The annual scientific and clinical Journal Impact Factors were released on June 30, and to say that our journal CA: A Cancer Journal for Clinicians outperformed is a vast understatement.
While not a surprise, it's certainly welcome news. CA is not only the leading journal for the entire oncology subject category but ranks highest for all 254 categories included in the Web of Science (clarivate.com).
CA’s score is due mainly to the global cancer statistics article and the annual report on cancer statistics, two of the most cited cancer articles in the world. These citations, factored along with a small number of publications, accounts for CA’s high score. Other highly cited manuscripts include the ACS screening guidelines, cancer statistics for special populations, and comprehensive reviews. You can find them here.
Our journal Cancer Cytopathology ranked No. 1 in the field of cytopathology. It scored 5.284. Our journal Cancer scored 6.860. Each journal falls within the top quartile of its subject category.
Below is a list of top 10 rankings for all oncology titles for 2018 and 2019, according to Clarivate:
2020 Journal Impact Factor (JIF)
CA-A CANCER JOURNAL FOR CLINICIANS
Nature Reviews Clinical Oncology
NATURE REVIEWS CANCER
JOURNAL OF CLINICAL ONCOLOGY
ANNALS OF ONCOLOGY
Bill Cance, MD, our chief medical and scientific officer, is editor in chief of CA: A Cancer Journal for Clinicians, and Ted Gansler, MD, MBA, MPH, is its editor.
It should be noted that this year's statistics show inflated scores across all titles due to a new calculation method used by Clarivate, but the scores are all relative and it does not diminish our standings.